Myriad Genetics Inc. (MYGN)

$18.51

-0.13

(-0.7%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Myriad Genetics Inc.

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 156.4M → 196.6M (in $), with an average increase of 4.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -116.1M → -31.2M (in $), with an average increase of 92.9% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 12.1% return, outperforming this stock by 26.1%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 5.4% return, outperforming this stock by 37.1%

Performance

  • $18.32
    $18.91
    $18.51
    downward going graph

    1.03%

    Downside

    Day's Volatility :3.09%

    Upside

    2.09%

    downward going graph
  • $13.82
    $24.21
    $18.51
    downward going graph

    25.34%

    Downside

    52 Weeks Volatility :42.92%

    Upside

    23.54%

    downward going graph

Returns

PeriodMyriad Genetics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-7.72%
-0.7%
0.0%
6 Months
23.77%
6.6%
0.0%
1 Year
-14.02%
3.7%
-1.5%
3 Years
-31.52%
14.0%
-21.8%

Highlights

Market Capitalization
1.7B
Book Value
$8.71
Earnings Per Share (EPS)
-3.18
PEG Ratio
1.4
Wall Street Target Price
24.36
Profit Margin
-34.96%
Operating Margin TTM
-12.56%
Return On Assets TTM
-7.4%
Return On Equity TTM
-31.55%
Revenue TTM
753.2M
Revenue Per Share TTM
9.1
Quarterly Revenue Growth YOY
10.6%
Gross Profit TTM
476.4M
EBITDA
-82.7M
Diluted Eps TTM
-3.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.3
EPS Estimate Next Year
-0.01
EPS Estimate Current Quarter
0.01
EPS Estimate Next Quarter
-0.04

Analyst Recommendation

Sell
    14%Buy
    42%Hold
    42%Sell
Based on 14 Wall street analysts offering stock ratings for Myriad Genetics Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
2
2
2
Hold
6
6
6
Sell
6
6
6

Analyst Forecast

What analysts predicted

Upside of 31.6%

Current $18.51
Target $24.36

Company Financials

FY18Y/Y Change
Revenue
772.6M
↑ 0.16%
Net Income
131.0M
↑ 500.92%
Net Profit Margin
16.96%
↑ 14.13%
FY19Y/Y Change
Revenue
851.1M
↑ 10.16%
Net Income
4.6M
↓ 96.49%
Net Profit Margin
0.54%
↓ 16.42%
FY20Y/Y Change
Revenue
851.1M
↑ 0.0%
Net Income
4.6M
↑ 0.0%
Net Profit Margin
0.54%
↑ 0.0%
FY21Y/Y Change
Revenue
557.0M
↓ 34.56%
Net Income
-223.7M
↓ 4963.04%
Net Profit Margin
-40.16%
↓ 40.7%
FY22Y/Y Change
Revenue
690.6M
↑ 23.99%
Net Income
-27.2M
↓ 87.84%
Net Profit Margin
-3.94%
↑ 36.22%
FY23Y/Y Change
Revenue
678.4M
↓ 1.77%
Net Income
-112.0M
↑ 311.76%
Net Profit Margin
-16.51%
↓ 12.57%
Q3 FY22Q/Q Change
Revenue
156.4M
↓ 12.77%
Net Income
-35.1M
↑ 148.94%
Net Profit Margin
-22.44%
↓ 14.58%
Q4 FY22Q/Q Change
Revenue
177.8M
↑ 13.68%
Net Income
-42.3M
↑ 20.51%
Net Profit Margin
-23.79%
↓ 1.35%
Q1 FY23Q/Q Change
Revenue
181.2M
↑ 1.91%
Net Income
-54.7M
↑ 29.31%
Net Profit Margin
-30.19%
↓ 6.4%
Q2 FY23Q/Q Change
Revenue
183.5M
↑ 1.27%
Net Income
-116.1M
↑ 112.25%
Net Profit Margin
-63.27%
↓ 33.08%
Q3 FY23Q/Q Change
Revenue
191.9M
↑ 4.58%
Net Income
-61.3M
↓ 47.2%
Net Profit Margin
-31.94%
↑ 31.33%
Q4 FY23Q/Q Change
Revenue
196.6M
↑ 2.45%
Net Income
-31.2M
↓ 49.1%
Net Profit Margin
-15.87%
↑ 16.07%
FY18Y/Y Change
Total Assets
1.2B
↓ 4.11%
Total Liabilities
209.2M
↓ 53.16%
FY19Y/Y Change
Total Assets
1.6B
↑ 33.1%
Total Liabilities
473.8M
↑ 126.48%
FY20Y/Y Change
Total Assets
1.6B
↑ 0.0%
Total Liabilities
473.8M
↑ 0.0%
FY21Y/Y Change
Total Assets
1.4B
↓ 9.21%
Total Liabilities
537.8M
↑ 13.51%
FY22Y/Y Change
Total Assets
1.3B
↓ 6.91%
Total Liabilities
352.9M
↓ 34.38%
FY23Y/Y Change
Total Assets
1.2B
↓ 9.24%
Total Liabilities
312.9M
↓ 11.33%
Q3 FY22Q/Q Change
Total Assets
1.2B
↑ 0.15%
Total Liabilities
295.4M
↑ 12.4%
Q4 FY22Q/Q Change
Total Assets
1.2B
↓ 1.1%
Total Liabilities
312.9M
↑ 5.92%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 2.45%
Total Liabilities
334.1M
↑ 6.78%
Q2 FY23Q/Q Change
Total Assets
1.2B
↑ 1.53%
Total Liabilities
452.0M
↑ 35.29%
Q3 FY23Q/Q Change
Total Assets
1.1B
↓ 3.21%
Total Liabilities
465.7M
↑ 3.03%
Q4 FY23Q/Q Change
Total Assets
1.1B
↓ 0.23%
Total Liabilities
363.3M
↓ 21.99%
FY18Y/Y Change
Operating Cash Flow
115.9M
↑ 9.13%
Investing Cash Flow
-11.6M
↓ 92.07%
Financing Cash Flow
-95.0M
↓ 232.31%
FY19Y/Y Change
Operating Cash Flow
83.7M
↓ 27.78%
Investing Cash Flow
-286.4M
↑ 2368.97%
Financing Cash Flow
182.3M
↓ 291.89%
FY20Y/Y Change
Operating Cash Flow
83.7M
↑ 0.0%
Investing Cash Flow
19.3M
↓ 106.74%
Financing Cash Flow
182.3M
↑ 0.0%
FY21Y/Y Change
Operating Cash Flow
-26.9M
↓ 132.14%
Investing Cash Flow
56.0M
↑ 190.16%
Financing Cash Flow
-1000.0K
↓ 100.55%
FY22Y/Y Change
Operating Cash Flow
18.2M
↓ 167.66%
Investing Cash Flow
274.4M
↑ 390.0%
Financing Cash Flow
-150.6M
↑ 14960.0%
FY23Y/Y Change
Operating Cash Flow
-106.3M
↓ 684.07%
Investing Cash Flow
-77.5M
↓ 128.24%
Financing Cash Flow
-8.0M
↓ 94.69%
Q3 FY22Q/Q Change
Operating Cash Flow
-1.8M
↓ 96.42%
Investing Cash Flow
11.4M
↓ 195.0%
Financing Cash Flow
-3.6M
↓ 244.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.7M
↑ 327.78%
Investing Cash Flow
-35.6M
↓ 412.28%
Financing Cash Flow
-2.1M
↓ 41.67%
Q1 FY23Q/Q Change
Operating Cash Flow
-33.2M
↑ 331.17%
Investing Cash Flow
34.6M
↓ 197.19%
Financing Cash Flow
-4.9M
↑ 133.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-900.0K
↓ 97.29%
Investing Cash Flow
11.8M
↓ 65.9%
Financing Cash Flow
38.4M
↓ 883.67%

Technicals Summary

Sell

Neutral

Buy

Myriad Genetics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Myriad Genetics Inc.
Myriad Genetics Inc.
-13.82%
23.77%
-14.02%
-31.52%
-41.84%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-9.73%
12.44%
-0.8%
-9.52%
118.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.9%
23.88%
-3.2%
0.79%
76.64%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-5.65%
17.12%
-6.43%
12.22%
110.66%
Danaher Corp.
Danaher Corp.
-4.8%
16.89%
-6.54%
-1.07%
88.84%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-10.49%
20.27%
12.09%
5.1%
70.85%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Myriad Genetics Inc.
Myriad Genetics Inc.
NA
NA
1.4
-0.3
-0.32
-0.07
NA
8.71
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.76
48.76
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
33.53
33.53
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.85
35.85
2.81
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
42.54
42.54
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
31.74
31.74
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Myriad Genetics Inc.
Myriad Genetics Inc.
Sell
$1.7B
-41.84%
NA
-34.96%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$40.7B
118.88%
48.76
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.1B
76.64%
33.53
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$211.7B
110.66%
35.85
13.99%
Danaher Corp.
Danaher Corp.
Buy
$178.0B
88.84%
42.54
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.1B
70.85%
31.74
9.06%

Institutional Holdings

  • BlackRock Inc

    16.31%

  • Vanguard Group Inc

    11.08%

  • Camber Capital Management LLC

    8.50%

  • Wellington Management Company LLP

    8.03%

  • Glenview Capital Management LLC

    5.88%

  • State Street Corporation

    5.23%

Corporate Announcements

  • Myriad Genetics Inc. Earnings

    Myriad Genetics Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.

Organization
Myriad Genetics Inc.
Employees
2700
CEO
Mr. Paul J. Diaz
Industry
Health Technology

Discover More

FAQs